The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], melphalan and prednisone) for the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for an autologous hematopoietic cell transplant.
"This approval is significant as we now have the first antibody-based regimen for treating newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant," said Andrzej Jakubowiak, MD, PhD, the